Citius Oncology, the oncology-focused subsidiary of Citius Pharmaceuticals, has announced a major step in its global expansion strategy, signing an exclusive distribution agreement with Uniphar, a leading international healthcare services company, to bring LYMPHIR (denileukin diftitox-cxdl) to European markets.

 

This marks Citius Oncology’s third international distribution partnership, reinforcing the company’s commitment to expanding access to its targeted immunotherapy outside the US.

 

Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories, managing market access and distribution through country-specific managed access programs. While LYMPHIR is not approved for commercial use outside the United States, the program will provide access where permitted by local law. Citius Oncology will supply the finished product and offer ongoing support.

 

“This agreement with Uniphar builds on the momentum of our international expansion efforts and reflects our commitment to partnering with experienced organizations that have deep regional expertise and proven execution capabilities,” said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. 

 

“As our third international distribution agreement, this partnership further strengthens our ability to responsibly expand access to LYMPHIR for patients with limited treatment options, while continuing to lay the groundwork for long-term global growth.”

 

Brian O'Shaughnessy, Chief Commercial Officer of Uniphar, added, “We are thrilled to partner with Citius Oncology to expand access to LYMPHIR across Europe. Uniphar is committed to connecting patients with innovative therapies, and this agreement strengthens our ability to support clinicians and improve outcomes for those living with or relapsed or refractory cutaneous T-cell lymphoma (CTCL).”

 

The Uniphar partnership follows Citius Oncology’s previous international agreements covering Southern Europe, the Balkans, Turkey, and the Middle East—underscoring a disciplined approach to global expansion through experienced regional partners.

 

LYMPHIR is a targeted immune therapy for relapsed or refractory CTCL in Stage I-III patients who have undergone at least one prior systemic therapy. It works by combining the IL-2 receptor binding domain with diphtheria toxin fragments to selectively kill cancerous T-cells and reduce immunosuppressive regulatory T lymphocytes. LYMPHIR received FDA approval and launched in the U.S. in December 2025, and it had previously been approved in Japan.